|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harirchi I, Kolahdoozan S, Karbakhsh M,
Chegini N, Mohseni SM, Montazeri A, Momtahen AJ, Kashefi A and
Ebrahimi M: Twenty years of breast cancer in Iran: Downstaging
without a formal screening program. Ann Oncol. 22:93–97. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashemi M, Fazaeli A, Ghavami S,
Eskandari-Nasab E, Arbabi F, Mashhadi MA, Taheri M, Chaabane W,
Jain MV and Łos MJ: Functional polymorphisms of FAS and FASL gene
and risk of breast cancer - pilot study of 134 cases. PLoS One.
8:e530752013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hashemi M, Eskandari-Nasab E, Fazaeli A,
Taheri M, Rezaei H, Mashhadi M, Arbabi F, Kaykhaei MA, Jahantigh M
and Bahari G: Association between polymorphisms of glutathione
S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk
in a sample Iranian population. Biomarkers Med. 6:797–803. 2012.
View Article : Google Scholar
|
|
5
|
Hashemi M, Eskandari-Nasab E, Fazaeli A,
Rezaei H, Mashhadi MA, Arbabi F and Taheri M: Bi-directional PCR
allele-specific amplification (bi-PASA) for detection of caspase-8
−652 6N ins/del promoter polymorphism (rs3834129) in breast cancer.
Gene. 505:176–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eskandari-Nasab E, Hashemi M, Rezaei H,
Fazaeli A, Mashhadi MA, Moghaddam SS, Arbabi F, Jahantigh M and
Taheri M: Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17)
and dihydrofolate reductase (DHFR) genes deletion and the
expression level of NGX6 mRNA in breast cancer. Mol Biol Rep.
39:10531–10539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Omrani M, Hashemi M, Eskandari-Nasab E,
Hasani SS, Mashhadi MA, Arbabi F and Taheri M: hsa-mir-499
rs3746444 gene polymorphism is associated with susceptibility to
breast cancer in an Iranian population. Biomarkers Med. 8:259–267.
2014. View Article : Google Scholar
|
|
8
|
Amininia S, Hashemi M, Ebrahimi M,
Mashhadi MA, Hashemi SM, Taheri M and Ghavami S: Association
between CCNE1 polymorphisms and the risk of breast cancer in a
sample of southeast Iranian population. Med Oncol. 31:1892014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voorhoeve PM, le Sage C, Schrier M, Gillis
AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A,
et al: A genetic screen implicates miRNA-372 and miRNA-373 as
oncogenes in testicular germ cell tumors. Cell. 124:1169–1181.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li YQ, Lu JH, Bao XM, Wang XF, Wu JH and
Hong WQ: miR-24 functions as a tumor suppressor in nasopharyngeal
carcinoma through targeting FSCN1. J Exp Clin Cancer Res.
34:1302015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruoming W, Zhen Y, Tengteng Z and Jisheng
H: Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by
targeting Smad4 and SGPP2. Cancer Gene Ther. 22:564–572. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Glover AR, Zhao JT, Gill AJ, Weiss J,
Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al:
MicroRNA-7 as a tumor suppressor and novel therapeutic for
adrenocortical carcinoma. Oncotarget. 6:36675–36688.
2015.PubMed/NCBI
|
|
16
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buscaglia LE and Li Y: Apoptosis and the
target genes of microRNA-21. Chin J Cancer. 30:371–380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hashemi M, Sheybani-Nasab M, Naderi M,
Roodbari F and Taheri M: Association of functional polymorphism at
the miR-502-binding site in the 3′ untranslated region of the SETD8
gene with risk of childhood acute lymphoblastic leukemia, a
preliminary report. Tumour Biol. 35:10375–10379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen
J, Liu S, Liu Z, Shi H, Shen H, et al: A potentially functional
polymorphism in the promoter region of miR-34b/c is associated with
an increased risk for primary hepatocellular carcinoma. Int J
Cancer. 128:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bossard P and Zaret KS: GATA transcription
factors as potentiators of gut endoderm differentiation.
Development. 125:4909–4917. 1998.PubMed/NCBI
|
|
21
|
Chou J, Provot S and Werb Z: GATA3 in
development and cancer differentiation: Cells GATA have it! J Cell
Physiol. 222:42–49. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu J, Yang L, You W, Cui X, Chen Y, Hu J,
Liu W, Li S, Song X, Wei Y, et al: Genetic variation in miR-100
rs1834306 is associated with decreased risk for esophageal squamous
cell carcinoma in Kazakh patients in northwest China. Int J Clin
Exp Pathol. 8:7332–7340. 2015.PubMed/NCBI
|
|
24
|
Zhang J, Huang X, Xiao J, Yang Y, Zhou Y,
Wang X, Liu Q, Yang J, Wang M, Qiu L, et al: Pri-miR-124 rs531564
and pri-miR-34b/c rs4938723 polymorphisms are associated with
decreased risk of esophageal squamous cell carcinoma in Chinese
populations. PLoS One. 9:e1000552014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji TX, Zhi C, Guo XG, Zhou Q, Wang GQ,
Chen B and Ma FF: miR-34b/c rs4938723 polymorphism significantly
decreases the risk of digestive tract cancer: Meta-analysis. Asian
Pac J Cancer Prev. 16:6099–6104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen P, Sun R, Pu Y, et al: Pri-Mir-34b/C
and Tp-53 polymorphisms are associated with the susceptibility of
papillary thyroid carcinoma: A case-control study. Medicine
(Baltimore). 94:e15362015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan XM, Sun RF, Li ZH, Guo XM, Qin HJ and
Gao LB: Pri-miR-34b/c rs4938723 polymorphism is associated with a
decreased risk of gastric cancer. Genet Test Mol Biomarkers.
19:198–202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin Z, Chen L, Song M, Shi KQ and Tang KF:
Association between a polymorphism in miR-34b/c and susceptibility
to cancer - a meta-analysis. Asian Pac J Cancer Prev. 15:7251–7255.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tao T, Chen S, Xu B, Liu C, Wang Y, Huang
Y and Chen M: Association between hsa-miR-34b/c rs4938723 T > C
promoter polymorphism and cancer risk: A meta-analysis based on
6,036 cases and 6,204 controls. Chin J Cancer Res. 26:315–322.
2014.PubMed/NCBI
|
|
30
|
Zhang S, Qian J, Cao Q, Li P, Wang M, Wang
J, Ju X, Meng X, Lu Q, Shao P, et al: A potentially functional
polymorphism in the promoter region of miR-34b/c is associated with
renal cell cancer risk in a Chinese population. Mutagenesis.
29:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang TJ, Liu HJ, Zhao XQ, Yu CH and Li
CS: Lack of association of miR-34b/c polymorphism (rs4938723) with
hepatocellular carcinoma: A meta-analysis. PLoS One. 8:e685882013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bensen JT, Tse CK, Nyante SJ,
Barnholtz-Sloan JS, Cole SR and Millikan RC: Association of
germline microRNA SNPs in pre-miRNA flanking region and breast
cancer risk and survival: The Carolina Breast Cancer Study. Cancer
Causes Control. 24:1099–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rezaei M, Hashemi M, Hashemi SM, Mashhadi
MA and Taheri M: APOBEC3 deletion is associated with breast cancer
risk in a sample of southeast Iranian population. Int J Mol Cell
Med. 4:103–108. 2015.PubMed/NCBI
|
|
34
|
Hashemi M, Hanafi Bojd H, Eskandari Nasab
E, Bahari A, Hashemzehi NA, Shafieipour S, Narouie B, Taheri M and
Ghavami S: Association of adiponectin rs1501299 and rs266729 gene
polymorphisms with nonalcoholic fatty liver disease. Hepat Mon.
13:e95272013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI,
Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, et al: Promoter
polymorphisms of pri-miR-34b/c are associated with hepatocellular
carcinoma. Gene. 524:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Q, Yang G, Song XL, Wang Z and Shi G:
Association between rs4938723 functional polymorphism in the
promoter region of miR-34b/c gene and cancer risk. Clin Res Hepatol
Gastroenterol. 39:526–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yi DH, Wang BG, Zhong XP, Liu H and Liu
YF: Pri-miR-34b/c rs4938723 TC heterozygote is associated with
increased cancer risks: Evidence from published data. Tumour Biol.
35:11967–11975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Lu X, Fang Y, Chen H, Deng X, Peng
C, Li H and Shen B: Association between miR34b/c polymorphism
rs4938723 and cancer risk: A meta-analysis of 11 studies including
6169 cases and 6337 controls. Med Sci Monit. 20:1977–1982. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tong N, Chu H, Wang M, Xue Y, Du M, Lu L,
Zhang H, Wang F, Fang Y, Li J, et al: Pri-miR-34b/c rs4938723
polymorphism contributes to acute lymphoblastic leukemia
susceptibility in Chinese children. Leuk Lymphoma. 57:1436–1441.
2016. View Article : Google Scholar : PubMed/NCBI
|
